Brief: Ocumension Therapeutics' Unit And Alimera Entered Into Exclusive License Agreement
14/04/2021 16:13
April 14 (Reuters) - Ocumension Therapeutics 1477.HK :
* UNIT AND ALIMERA ENTERED INTO EXCLUSIVE LICENSE AGREEMENT
* CONSIDERATION INCLUDES UPFRONT PAYMENT IN AMOUNT OF US$10
MLN
* CONSIDERATION ALSO INCLUDES AGGREGATED POTENTIAL SALES
MILESTONE
PAYMENT IN AMOUNT OF UP TO US$89 MLN
* ALIMERA TO GRANT GROUP LICENSING RIGHTS OF ALIMERA'S 190
MICROGRAM FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN
APPLICATOR
Source text for Eikon: ID:nHKS2p5NCP
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger